“Akt–the Mammalian Target of Rapamycin (mTOR) Pathway Inhibition Increases Cervical Cancer Cell Chemosensitivity to Active Form of Irinotecan (SN-38)”. International Journal of Integrated Health Sciences 1, no. 1 (September 17, 2013): 13–21. Accessed July 18, 2026. https://journal.fk.unpad.ac.id/index.php/ijihs/article/view/103.